Quarterly Appendix 4C and Activities Report
Filed with ASX · · 10 pages · English
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- US Patent Granted for Galidesivir in filoviridae viruses
- Ongoing engagement with the US FDA
- Agreement with Texas Biomed for Galidesivir Program
- Island expands Galidesivir IP with US Patent Grant
- Additional FDA Submission completed for Galidesivir
Later from Island Pharmaceuticals
- FDA confirms Galidesivir approval pathway
- $9m placement to advance US biodefence opportunity
- Response to ASX Query Letter
- Appendix 4D & Half-Year Financial Statements
- Trading Halt
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals